Angiomax (bivalirudin)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Angiomax (bivalirudin), covering 2017-02-27 to 2017-02-27. Get the full timeline:
Most recent: Clinical Trial Update: Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH [Phase 3]